Policy & Regulation
Daiichi Sankyo Company launches MINNEBRO
15 May 2019 -

Daiichi Sankyo Company, a subsidiary of US-based Exelixis, Inc (Nasdaq: EXEL), has introduced its MINNEBRO (esaxerenone) tablets for the treatment of hypertension, it was reported yesterday.

With Daiichi Sankyo's first commercial sale of the product in Japan, Exelixis will receive an associated USD20m milestone payment from Daiichi Sankyo under the terms of the companies' collaboration agreement.

Exelixis anticipates receiving the payment during the second quarter of 2019.

The product is a novel mineralocorticoid receptor blocker identified through Exelixis and Daiichi Sankyo research and developed and commercialised by Daiichi Sankyo.